Published April 28, 2023 | Version v1
Journal article Open

The Results of Surgical Treatment of Patients with Many Valve Defects in Combination with Coronary Pathology

Creators

  • 1. State Institution «Amosov National Institute of Cardiovascular Surgery of the National Academy of Medical Sciences of Ukraine», Ukraine

Description

The objective: to analyze the impact of various surgical management on the duration of the ischemic period and the quality of myocardial protection during simultaneous combined correction of two-three heart valves and myocardial revascularization.

Materials and methods. The results of the treatment of single-stage multivalve correction in combination with coronary artery bypass grafting in 93 patients, which was performed at the M.M. Amosov National Institute of Cardiovascular Surgery for the period from 2014 to 2021, were studied.

Depending on the methods and the sequence of surgical manipulations, the patients were divided into three groups. I group – 42 patients who had the correction of heart valves firstly and then aortocoronary shunting in conditions of pharmaco-cold cardiac arrest, II group – 36 patients who first had aortocoronary bypass surgery, then valve correction in conditions of pharmaco-cold cardiac arrest, III group – 15 patients, who at the first stage had coronary artery bypass grafting on a working heart, then – correction of valve damage in conditions of pharmaco-cold cardiac arrest.

Results. The use of the technique of primary restoration of coronary blood flow by shunting coronary arteries in a working heart before clamping the aorta (before pharmaco-cold cardiac arrest and the start of artificial blood circulation) allows to reduce the duration of artificial blood flow and ischemic time, which positively affects the heart rhythm in the postoperative period.

Conclusions. The technique of performing aortocoronary shunting on a working heart is more effective than when performing aortocoronary shunting in conditions of pharmaco-cold cardiac arrest. This technique requires more time to perform and is technically more difficult, but it can statistically significantly reduce the time of myocardial ischemia, which reduces the frequency of severe heart failure and the frequency of postoperative complications.

Files

The_Results_of_Surgical_Treatment_of_Patients_with_Many_Valve_Defects_in_Combination_with_Coronary_Pathology.pdf

Files (1.6 MB)

Additional details

References

  • Okba A, Al Kaabi LS, Kakamad FH, Rawezh S. Early outcome of combined coronary artery bypass grafting and valve surgery. Edorium J Cardiothorac Vasc Surg 2018;5:100013C04OA.
  • Rankin JS, Badhwar V, He X, Jacobs JP, Gammie JS, Furnary AP, et al. The Society of Thoracic Surgeons Mitral Valve Repair/Replacement Plus Coronary Artery Bypass Grafting Composite Score: A Report of The Society of Thoracic Surgeons Quality Measurement Task Force. Ann Thorac Surg. 2017;103(5):1475–81. doi: 10.1016/j.athoracsur.2016.09.035.
  • Binder A, Ali A, Chawla R, Aziz HA, Abbate A, Jovin IS. Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Rev Cardiovasc Ther. 2015;13(9):1045–57. doi: 10.1586/14779072.2015.1070669.
  • Davidson SM, Ferdinandy P, Andreadou I, Botker HE, Heusch G, Ibáñez B, et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(1):89–99. doi: 10.1016/j.jacc.2018.09.086.
  • Landoni G, Zangrillo A, Lomivorotov VV, Likhvantsev V, Ma J, De Simone F, Fominskiy E. Cardiac protection with phosphocreatine: a meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(4):637–46. doi: 10.1093/icvts/ivw171.
  • Ursulenko VI, Kupchynskyi OV, Naumova LR, Starodub YuS, Semeniv PM, Galyuk VM, et al. Options and ways to protect myocardium in surgical treatment of valvular heart disease combined with coronary pathology. Heart and blood vessels. 2017;(2):61–8.
  • El Sabbagh A, Nishimura RA. Clinical Conundrum of Coronary Artery Disease and Aortic Valve Stenosis. J Am Heart Assoc. 2017;6(2):e005593. doi: 10.1161/JAHA.117.005593.
  • Trenkwalder T, Nelson CP, Musameh MD, Mordi IR, Kessler T, Pellegrini C, et al. Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. Int J Cardiol. 2019;276:212–7. doi: 10.1016/j.ijcard.2018.11.094.
  • Loop FD, Higgins TL, Panda R, Pearce G, Estafanous FG. Myocardial protection during cardiac operations. Decreased morbidity and lower cost with blood cardioplegia and coronary sinus perfusion. J Thorac Cardiovasc Surg. 1992;104(3):608–18. PMID: 1513150.
  • Baikoussis NG, Papakonstantinou NA, Verra C, Kakouris G, Chounti M, Hountis P, et al. Mechanisms of oxidative stress and myocardial protection during open-heart surgery. Ann Card Anaesth. 2015;18(4):555–64. doi: 10.4103/0971-9784.166465.
  • Trummer G, Benk C, Beyersdorf F. Controlled automated reperfusion of the whole body after cardiac arrest. J Thorac Dis. 2019;11(10):1464–70. doi: 10.21037/jtd.2019.04.05.
  • Singh N, Gimpel D, Chan B, McCormack DJ, El-GamelIs A. Custodiol Cardioplegia Superior to Blood Cardioplegia? A Systematic Review and Meta-Analysis. Heart Lungs Circul. 2019;28(3):114. doi: 10.1016/j.hlc.2019.02.139.
  • Kohlhauer M, Pell VR, Burger N, Spiroski AM, Gruszczyk A, Mulvey JF, et al. Protection against cardiac ischemia-reperfusion injury by hypothermia and by inhibition of succinate accumulation and oxidation is additive. Basic Res Cardiol. 2019;114(3):18. doi: 10.1007/s00395-019-0727-0.
  • Liu NB, Wu M, Chen C, Fujino M, Huang JS, Zhu P, et al. Novel Molecular Targets Participating in Myocardial Ischemia-Reperfusion Injury and Cardioprotection. Cardiol Res Pract. 2019;2019:6935147. doi: 10.1155/2019/6935147.
  • Hoyer A, Kiefer P, Borger M. Cardioplegia and myocardial protection: time for a reassessment? J Thorac Dis. 2019;11(5):E76–E78. doi: 10.21037/jtd.2019.05.08.
  • Khana AH, Abbasb S, Naizic AK, Iqbalc M. Effect of route of cardioplegia delivery on myocardial protection. J Cardiovasc Dis. 2015;13(1):10–3.
  • Essandoh M. Myocardial Protection During Minimally Invasive Mitral Valve Surgery: Is Retrograde Cardioplegia Alone Enough? J Cardiothoracic Vascular Anesthesia. 2019;33(8):2362.
  • Kamassai JD, Lowery DR. Cleveland Clinic/Uniformed Services Un. Retrograde Cardioplegia [Internet]. Treasure Island (FL): StatPearls Publishing. 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538289/.
  • Costa FDAD, Colatusso DFF, Martin GLDS, Parra KCS, Botta MC, Balbi Filho EM, Veloso M, Miotto G, Ferreira ADA, Colatusso C. Long-Term Results of Mitral Valve Repair. Braz J Cardiovasc Surg. 2018;33(1):23–31. doi: 10.21470/1678-9741-2017-0145.
  • Kim BJ, Kim YS, Kim HJ, Ju MH, Kim JB, Jung SH, Choo SJ, Chung CH. Concomitant mitral valve surgery in patients with moderate ischemic mitral regurgitation undergoing coronary artery bypass grafting. J Thorac Dis. 2018;10(6):3632–42. doi: 10.21037/jtd.2018.05.148.
  • Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, O'Neill N, et al. The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasESeries in Surgery (PROCESS) Guidelines. Int J Surg. 2020;84:231–5. doi: 10.1016/j.ijsu.2020.11.005.
  • Kaliyev R, Lesbekov T, Bekbossynov S, Bekbossynova M, Nurmykhametova Z, Novikova S, et al. Comparison of Custodiol vs warm blood cardioplegia and conditioning of donor hearts during transportation with the organ care system. J Card Surg. 2019;34(10):969–975. doi: 10.1111/jocs.14162.
  • Herlitz J, Brandrup-Wognsen G, Caidahl K, Haglid M, Karlsson BW, Karlsson T, et al. Mortality and morbidity among patients who undergo combined valve and coronary artery bypass surgery: early and late results. Eur J Cardiothorac Surg. 1997;12(6):836–46. doi: 10.1016/s1010-7940(97)00278-9.
  • Teng Z, Ma X, Zhang Q, Yun Y, Ma C, Hu S, et al. Additional mitral valve procedure and coronary artery bypass grafting versus isolated coronary artery bypass grafting in the management of significant functional ischemic mitral regurgitation: a meta-analysis. J Cardiovasc Surg (Torino). 2017;58(1):121–30. doi: 10.23736/S0021-9509.16.08852-2.
  • Gatti G, Rauber E, Forti G, Benussi B, Gabrielli M, Gripari C, et al. Safe cross-clamp time using CustodiolR-histidinetryptophan-ketoglutarate cardioplegia in the adult. Perfusion. 2019;34(7):568–77. doi: 10.1177/0267659119837824.